Home›Research›Compare›CJC-1295 (without DAC) vs IGF-1 LR3
Peptide ComparisonCJC-1295 (without DAC) vs IGF-1 LR3
Both are GH / IGF Axis peptides.
CJC-1295 (without DAC)
CJC 1295
Half-life: ~30 minutes
501 providers listed
IGF-1 LR3
IGF1 LR3
Half-life: 20–30 hours
92 providers listed
CJC-1295 (without DAC) has published research citations on file; IGF-1 LR3 does not yet — the main evidence gap between them.
CJC-1295 (without DAC)
Half-life
~30 minutes
IGF-1 LR3
Half-life
20–30 hours
| Your goal | Better option |
|---|---|
| Has published research citations | CJC-1295 (without DAC) |
| Less frequent dosing (longer half-life) | IGF-1 LR3 |
| More provider options (501 vs 92) | CJC-1295 (without DAC) |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
CJC-1295 (without DAC)
IGF-1 LR3
CJC-1295 (without DAC)
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…
Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…
IGF-1 LR3
No citations on file.
About CJC-1295 (without DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.
About IGF-1 LR3
Long-acting analog of IGF-1 that binds to IGF-1 receptors, promoting muscle protein synthesis, cellular growth, and recovery. Suppresses myostatin activity and has a significantly extended half-life compared to native IGF-1 due to reduced binding protein affinity.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CJC-1295 (without DAC)
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceIGF-1 LR3
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
CJC-1295 (without DAC)
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
CJC-1295 (without DAC)
IGF-1 LR3
Not enough vendor pricing yet.
Where to source these peptides
CJC-1295 (without DAC)
501 listed
Browse directory →
Providers offeringIGF-1 LR3
92 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More GH / IGF Axis Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated October 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CJC-1295 (without DAC) vs IGF-1 LR3 — Per-mg Price Comparison. Retrieved October 27, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/igf-1-lr3